Articles related to Gastroenterology

FDA Approves Optune Pax® in Combination with Chemotherapy for Locally Advanced Pancreatic Cancer

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement

Gastroenterology February 17th 2026

Tags: CHEMOTHERAPY COMBINATION THERAPY DEVICE/DRUG APPROVALS PALLIATIVE CARE PANCREATIC CANCER SURGICAL ONCOLOGY

Medical News Today (MNT)

Two Days of Oatmeal May Help Reduce ‘Bad’ Cholesterol Levels, Study Finds

The researchers found that simply including oats into a daily meal plan did not produce measurable changes in LDL or overall cholesterol levels after six weeks.

Cardiology February 6th 2026

Tags: DIET & NUTRITION DIGESTIVE/GUT HEALTH LIPID HEALTH PATIENT EDUCATION PREVENTIVE MEDICINE STATINS/CHOLESTEROL MANAGEMENT

Epoch Health

How to Eat Using the New ‘Inverted’ Food Pyramid

“The most striking changes rarely show up first in lab results; they show up in how people feel on Tuesday afternoon and Thursday night.” – Sheridan Genrich, nutritionist

Endocrinology, Diabetes, Metabolism January 27th 2026

Tags: DIET & NUTRITION GUIDELINES/RECOMMENDATIONS PATIENT EDUCATION PRENATAL CARE

MDLinx

Major Malpractice Suit Due to…Doc’s Hidden Dementia? Who’s to Blame?

The lawsuit against Scott Wiesen, MD, from patient Elaine Bredehoft said this: “He was suffering from dementia and was not able to recognize long-term employees of his practice.”

Gastroenterology January 22nd 2026

Tags: ALZHEIMER'S/DEMENTIA COGNITIVE HEALTH/MEMORY LEGAL MATTERS MALPRACTICE MEDICAL ETHICS RISK MANAGEMENT

Medical Xpress

Pancreatic Cancer Forms ‘Synapses,’ Scientists Discover

When glutamate binds to the cancer cells’ NMDA receptors, a channel opens and calcium flows into the cell. This influx triggers molecular signaling cascades that drive tumor growth and metastasis.

Gastroenterology November 17th 2025

Tags: PANCREATIC CANCER RESEARCH & CLINICAL TRIALS TARGETED THERAPIES

Conexiant

FDA Approves First Pediatric IBS-C Treatment

Linzess is the first treatment approved for IBS-C in pediatric patients. Patients younger than 2 years can be at risk of serious dehydration and should not take Linzess for any indication.

Family Medicine/General Practice November 17th 2025

Tags: DEVICE/DRUG APPROVALS DIARRHEA IRRITABLE BOWEL SYNDROME (IBS) PEDIATRIC GASTROENTEROLOGY

1 2 … 49 50 >>

Trending Topics:

Articles related to Gastroenterology

View More Articles On:

FDA Approves Optune Pax® in Combination with Chemotherapy for Locally Advanced Pancreatic Cancer

Two Days of Oatmeal May Help Reduce ‘Bad’ Cholesterol Levels, Study Finds

How to Eat Using the New ‘Inverted’ Food Pyramid

Major Malpractice Suit Due to…Doc’s Hidden Dementia? Who’s to Blame?

Pancreatic Cancer Forms ‘Synapses,’ Scientists Discover

FDA Approves First Pediatric IBS-C Treatment

Topics

Sources

The Healthcare Communications Network is owned and operated by IQVIA Inc. Click below to leave this site and continue to IQVIA’s Privacy Choices form

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form